Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use: a quasi-experimental study in a region of high MRSA prevalence

Pyoeng Gyun Choe, Hei Lim Koo, Doran Yoon, Ji Yun Bae, Eunyoung Lee, Joo-Hee Hwang, Kyoung-Ho Song, Wan Beom Park, Ji Hwan Bang, Eu Suk Kim, Hong Bin Kim, Sang Won Park, Myoung-Don Oh, Nam Joong Kim, Pyoeng Gyun Choe, Hei Lim Koo, Doran Yoon, Ji Yun Bae, Eunyoung Lee, Joo-Hee Hwang, Kyoung-Ho Song, Wan Beom Park, Ji Hwan Bang, Eu Suk Kim, Hong Bin Kim, Sang Won Park, Myoung-Don Oh, Nam Joong Kim

Abstract

Background: Despite vancomycin use is a major risk factor for the emergence of vancomycin resistance, it is frequently inappropriately prescribed, especially as empirical treatment. We evaluated the effect of an antimicrobial stewardship intervention targeting for inappropriate continued empirical vancomycin use.

Methods: This was a quasi-experimental study comparing vancomycin use in a 6-month pre-intervention and 6-month intervention period. If empirical vancomycin was continued for more than 96 h without documentation of beta-lactam-resistant gram-positive microorganisms, it was considered inappropriate continued empirical vancomycin use. The intervention consisted of the monitoring of appropriateness by a pharmacist and direct discussion with the prescribing physicians by infectious disease specialists when empirical vancomycin was continued inappropriately. An interrupted time series analysis was used to compare vancomycin use before and during the intervention.

Results: Following implementation of the intervention, overall vancomycin consumption decreased by 14.6%, from 37.6 defined daily doses (DDDs)/1000 patient-days in the pre-intervention period to 32.1 DDDs/1000 patient-days in the intervention period (P < 0.001). The inappropriate consumption of vancomycin also declined from 8.0 DDDs/1000 patient-days to 5.8 DDDs/1000 patient-days (P = 0.009).

Conclusion: Interventions such as direct communication with prescribing physicians and infectious disease clinicians can help reduce the inappropriate continued use of vancomycin.

Keywords: Antimicrobial stewardship; Inappropriate use; Infectious disease specialist; Intervention; Pharmacist; Vancomycin.

Conflict of interest statement

Ethics approval and consent to participate

The institutional review board of Seoul National University Hospital reviewed the study protocol and provided study approval. It waived the requirement for written consent (IRB registration number 1407–043-593).

Competing interests

The authors declare that they have no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Vancomycin consumption and appropriateness in the pre-intervention and intervention periods

References

    1. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med. 1999;159(20):2461–2468. doi: 10.1001/archinte.159.20.2461.
    1. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol. 2003;24(9):690–698. doi: 10.1086/502271.
    1. Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016;11(12):2132–2140. doi: 10.2215/CJN.05920616.
    1. The Hospital Infection Control Practice Advisory Committee Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) Am J Infect Control. 1995;23(2):87–94. doi: 10.1016/0196-6553(95)90104-3.
    1. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011;26(2):220–252. doi: 10.3904/kjim.2011.26.2.220.
    1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with Cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi: 10.1093/cid/ciq147.
    1. Junior MS, Correa L, Marra AR, Camargo LF, Pereira CA. Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study. BMC Infect Dis. 2007;7:88. doi: 10.1186/1471-2334-7-88.
    1. Melo DO, Ribeiro E. Vancomycin use in a Brazilian teaching hospital: comparison with the hospital infection Controlpractices advisory committee guidelines (HICPAC) Braz J Infect Dis. 2009;13(3):161–164. doi: 10.1590/S1413-86702009000300001.
    1. Islahudin F, Ong HY. Appropriate vancomycin use in a Malaysian tertiary hospital based on current HICPAC recommendations. J Infect Dev Ctries. 2014;8(10):1267–1271. doi: 10.3855/jidc.4676.
    1. Magill SS, Edwards JR, Beldavs ZG, Dumyati G, Janelle SJ, Kainer MA, et al. Prevalence of antimicrobial use in US acute care hospitals, may-September 2011. JAMA. 2014;312(14):1438–1446. doi: 10.1001/jama.2014.12923.
    1. Bollinger M, Hamilton M, Schroeder K, Link S, Nguyen J, Chu D, et al. Vancomycin use in a rural hospital: a 3-year retrospective study. Can J Rural Med. 2015;20(2):56–62.
    1. Kim NH, Hwang JH, Song KH, Choe PG, Park WB, Kim ES, et al. Changes in antimicrobial susceptibility of blood isolates in a University Hospital in South Korea, 1998-2010. Infect Chemother. 2012;44(4):275–281. doi: 10.3947/ic.2012.44.4.275.
    1. Jun KI, Koo HL, Kim MK, Kang CK, Kim MJ, Chun SH, et al. Trends in antibiotic use in a single university hospital. Korean J Nosocomial Infect Control. 2013;18(2):44–50. doi: 10.14192/kjnic.2013.18.2.44.
    1. Kim NH, Koo HL, Choe PG, Cheon S, Kim M, Lee MJ, et al. Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59(2):811–817. doi: 10.1128/AAC.04523-14.
    1. Maxwell M, Heaney D, Howie JG, Noble S. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. Br Med J. 1993;307(6913):1190–1194. doi: 10.1136/bmj.307.6913.1190.
    1. Hamilton CD, Drew R, Janning SW, Latour JK, Hayward S. Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol. 2000;21(1):42–45. doi: 10.1086/501703.
    1. Chan S, Hossain J, Di Pentima MC. Implications and impact of prior authorization policy on vancomycin use at a tertiary pediatric teaching hospital. Pediatr Infect Dis J. 2015;34(5):506–508. doi: 10.1097/INF.0000000000000615.
    1. Guglielmo BJ, Dudas V, Maewal I, Young R, Hilts A, Villmann M, et al. Impact of a series of interventions in vancomycin prescribing on use and prevalence of vancomycin-resistant enterococci. Jt Comm J Qual Patient Saf. 2005;31(8):469–475. doi: 10.1016/S1553-7250(05)31061-0.
    1. Bolon MK, Arnold AD, Feldman HA, Goldmann DA, Wright SB. An antibiotic order form intervention does not improve or reduce vancomycin use. Pediatr Infect Dis J. 2005;24(12):1053–1058. doi: 10.1097/01.inf.0000190025.61037.6c.
    1. Misan GM, Martin ED, Smith ER, Somogyi AA, Bartholomeusz RC, Bochner F. Drug utilization review in a teaching hospital: experience with vancomycin. Eur J Clin Pharmacol. 1990;39(5):457–461. doi: 10.1007/BF00280936.
    1. Yoon YK, Park CS, Kim JW, Hwang K, Lee SY, Kim TH, et al. Guidelines for the antibiotic use in adults with acute upper respiratory tract infections. Infect Chemother. 2017;49(4):326–352. doi: 10.3947/ic.2017.49.4.326.
    1. Kwak YG, Choi SH, Kim T, Park SY, Seo SH, Kim MB, et al. Clinical guidelines for the antibiotic treatment for community-acquired skin and soft tissue infection. Infect Chemother. 2017;49(4):301–325. doi: 10.3947/ic.2017.49.4.301.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться